ASBrS: Less-invasive mastectomy safe for more women
A type of mastectomy that leaves the surface of the breast intact is a safe...Read more on AuntMinnie.comRelated Reading: Contrast mammo equals MRI for measuring tumor size Racial factors affect time to breast cancer treatment Breast MRI helps guide DCIS treatment Women still need breast imaging after mastectomy Breast cancer follow-up imaging varies widely
ConclusionsLong-term breast reconstruction complication rates are higher than previously anticipated, with increased rates of complications noted in the IBBR group. Patients should be counseled that IBBR is associated with higher rates of complications, including unplanned return to the OR, compared to ATR.
Conclusions: This study provides a first overview of available registry data on breast cancer care in The Netherlands and the United States, and revealed limited data on treatment in the United States. Comparison of treatment patterns of immediate breast reconstruction showed interesting differences. The authors advocate the urgency for an international database with alignment of (treatment) variables to improve quality of breast cancer care for patients across the globe.
This 61-year-old woman presented with new primary triple negative breast cancer (TNBC) in the lateral breast 10 years after completing radiation for ductal carcinoma in situ (DCIS) in the same breast.1 Despite neoadjuvant chemotherapy and mastectomy with only residual DCIS and negative nodes, patient developed a TNBC re-recurrence only 9 months later. She was treated with chemotherapy, and there remains positive residual localized disease by positron emission tomography (PET). At this point we recommend the following.
ConclusionsA novel system using supine MRI images co-registered with intraoperative optical scanning and tracking enabled tumors to be resected with a trend toward a lower positive margin rate compared with wire-localized partial mastectomy. Margin positivity was more likely when imaging underestimated pathologic tumor size.
ConclusionWe observed a low complication rate in 94 consecutive RNSM procedures, demonstrating the procedure is technically feasible and safe. We found no early local failures at 19 months follow-up. Long-term follow-up is needed to confirm oncologic safety. Future clinical trials to study the advantages and disadvantages of RNSM are warranted.
The prognosis of ductal carcinoma in situ (DCIS) is reportedly well. Extremely rare patients with DCIS develop distant breast cancer metastasis without locoregional or contralateral recurrence. This is the fir...
Abstract To clarify the surgical outcomes of breast cancer patients with a preoperative diagnosis of ductal carcinoma in situ (DCIS) by core needle biopsy (CNB) (abbreviated as CNBDCIS), we retrospectively analyzed the cases of 131 patients with CNBDCIS who underwent surgery at Oomoto Hospital (32 total mastectomies, 99 conservative mastectomies). Our analysis of underestimation and predictors of invasive breast cancer of CNBDCIS revealed that the underestimation rate of CNBDCIS was 40.5% (53/131). A logistic regression analysis revealed that palpable tumors (yes to no, odds ratio [OR] 3.25), mammography (MMG) cat...
Conclusions: Immediate reconstruction for unilateral mastectomy and contralateral prophylactic mastectomy have similar complication risk profiles, among patients as a whole and between individual breasts. These findings contribute to our understanding of the clinical impact prophylactic mastectomy and reconstruction may have on optimizing the counseling among extirpative surgeons, reconstructive surgeons, and patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Abstract PURPOSE: Ductal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to analyze the clinicopathological characteristics and clinical outcomes of coexisting DCIS component in IDC and its clinical significance according to molecular subtypes. METHODS: Data from 3001 patients with IDC (79.4%) and IDC/DCIS (20.6%) who underwent surgery from January 2009 to June 2016 were retrospectively assessed. The clinical outcomes of IDC with coexistent DCIS in different molecular subtypes were evaluated. RESULTS: IDC/DCIS patients were more likely to be younger (P
AbstractPurposeDuctal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to analyze the clinicopathological characteristics and clinical outcomes of coexisting DCIS component in IDC and its clinical significance according to molecular subtypes.MethodsData from 3001 patients with IDC (79.4%) and IDC/DCIS (20.6%) who underwent surgery from January 2009 to June 2016 were retrospectively assessed. The clinical outcomes of IDC with coexistent DCIS in different molecular subtypes were evaluated.ResultsIDC/DCIS patients were more likely to be younger (P